173 related articles for article (PubMed ID: 32619790)
1. Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome.
Rentas S; Pillai V; Wertheim GB; Akgumus GT; Nichols KE; Deardorff MA; Conlin LK; Li MM; Olson TS; Luo M
Cancer Genet; 2020 Jul; 245():42-48. PubMed ID: 32619790
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations.
Ahmed IA; Farooqi MS; Vander Lugt MT; Boklan J; Rose M; Friehling ED; Triplett B; Lieuw K; Saldana BD; Smith CM; Schwartz JR; Goyal RK
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2186-2196. PubMed ID: 31306780
[TBL] [Abstract][Full Text] [Related]
3. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
4. Emerging phenotypes linked to variants in
Suntharalingham JP; Ishida M; Del Valle I; Stalman SE; Solanky N; Wakeling E; Moore GE; Achermann JC; Buonocore F
Front Endocrinol (Lausanne); 2022; 13():953707. PubMed ID: 36060959
[TBL] [Abstract][Full Text] [Related]
5. Hereditary Predispositions to Myelodysplastic Syndrome.
Bannon SA; DiNardo CD
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27248996
[TBL] [Abstract][Full Text] [Related]
6. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
7. In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
Hockings C; Gohil S; Dowse R; Hoade Y; Mansour MR; Gale RE; Linch DC; Rao A; Payne EM
Br J Haematol; 2020 Feb; 188(4):e53-e57. PubMed ID: 31900929
[No Abstract] [Full Text] [Related]
8. Somatic mosaic monosomy 7 and UPD7q in a child with MIRAGE syndrome caused by a novel SAMD9 mutation.
Csillag B; Ilencikova D; Meissl M; Webersinke G; Laccone F; Narumi S; Haas O; Duba HC
Pediatr Blood Cancer; 2019 Apr; 66(4):e27589. PubMed ID: 30565860
[TBL] [Abstract][Full Text] [Related]
9. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
10. A novel SAMD9 variant identified in patient with MIRAGE syndrome: Further defining syndromic phenotype and review of previous cases.
Perisa MP; Rose MJ; Varga E; Kamboj MK; Spencer JD; Bajwa RPS
Pediatr Blood Cancer; 2019 Jul; 66(7):e27726. PubMed ID: 30900330
[TBL] [Abstract][Full Text] [Related]
11. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
13. Germline ETV6 mutations and predisposition to hematological malignancies.
Feurstein S; Godley LA
Int J Hematol; 2017 Aug; 106(2):189-195. PubMed ID: 28555414
[TBL] [Abstract][Full Text] [Related]
14. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
15. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
Babushok DV; Bessler M; Olson TS
Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
[TBL] [Abstract][Full Text] [Related]
16. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.
Wong JC; Bryant V; Lamprecht T; Ma J; Walsh M; Schwartz J; Del Pilar Alzamora M; Mullighan CG; Loh ML; Ribeiro R; Downing JR; Carroll WL; Davis J; Gold S; Rogers PC; Israels S; Yanofsky R; Shannon K; Klco JM
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046003
[TBL] [Abstract][Full Text] [Related]
17. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
19. [Genetic abnormalities in myelodysplastic syndrome].
Ogawa S
Rinsho Ketsueki; 2005 Jun; 46(6):439-52. PubMed ID: 16447726
[No Abstract] [Full Text] [Related]
20. [Novel germline SAMD9 mutation in an elderly patient with myelodysplastic syndrome].
Uchida T; Fujii T; Ohara S; Imai Y; Inoue M; Harada Y; Harada H; Hagihara M
Rinsho Ketsueki; 2022; 63(8):865-869. PubMed ID: 36058856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
